# Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer

> **NCT03329378** · PHASE2 · TERMINATED · sponsor: **Icahn School of Medicine at Mount Sinai** · enrollment: 7 (actual)

## Conditions studied

- Locally Advanced Breast Cancer

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Carboplatin
- **DRUG:** Trastuzumab
- **DRUG:** Pertuzumab
- **DRUG:** Pegfilgrastim
- **DRUG:** Trastuzumab
- **DRUG:** Paclitaxel
- **DRUG:** Doxorubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT03329378
- **Lead sponsor:** Icahn School of Medicine at Mount Sinai
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-01-24
- **Primary completion:** 2021-03-07
- **Final completion:** 2021-03-07
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Data Safety Monitoring Board is in agreement with the study findings so far and the stopping rule has been met, which suspends the study treatment arms in March 2021.
- **Last updated:** 2023-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03329378

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03329378, "Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03329378. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*